We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia (LLC2007SA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00645606
First Posted: March 27, 2008
Last Update Posted: August 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Roche Pharma AG
French Innovative Leukemia Organisation
Information provided by (Responsible Party):
University Hospital, Tours
March 26, 2008
March 27, 2008
August 1, 2017
December 2007
February 2014   (Final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: randomization until disease progression or death ]
Progression-free survival is defined as the time from randomization to the first occurrence of disease progression, relapse or death from any cause; using iwCLL criteria
Three-year progression-free survival
Complete list of historical versions of study NCT00645606 on ClinicalTrials.gov Archive Site
  • Event-free survival [ Time Frame: randomization until disease progression, death, new CLL treatment, and secondary cancer ]
    Event-free survival is defined as the time from randomization to the occurrence of one of the following events, whichever occurs first: disease progression or relapse, death from any cause, initiation of any new anti-CLL therapy, and secondary malignancy
  • Disease-free survival [ Time Frame: first documented CR until relapse ]
    Disease-free survival is defined as the time from first documented CR to relapse
  • Overall survival [ Time Frame: randomization until death ]
    Overall survival is defined as the time from randomization to death from any cause
  • Time to next treatment [ Time Frame: randomization until new CLL treatment ]
    Time to next treatment is defined as the time from randomization to initiation of a new CLL-related treatment
  • Overall response rate [ Time Frame: baseline up to approximately 66 months ]
    Overall response rate is defined by the percentage of participants with an overall response; CR or PR according to NCI criteria and CR, CRi or PR according to iwCLL
  • Phenotypic response rate [ Time Frame: randomization up to approximately 60 months ]
    Phenotypic response rate is defined by the percentage of participants with minimal residual disease negativity as measured by six-colour flow cytometry with a sensitivity of 0.7 x 10-5. MRD is considered as undetectable when the positivity criteria, defined as the presence of at least 20 CLL cells, is not reached
  • Rates of treatment-related adverse events [ Time Frame: safety since baseline ]
    Rate of treatment-related adverse events (plus adverse events of particular interest) is defined as the percentage of participants with adverse events assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and version 2.0. for hematological toxicity
  • Pharmacokinetics of rituximab [ Time Frame: baseline up to approximately 36 months ]
    Pharmacokinetics of rituximab during induction and rituximab maintenance
  • Quality of life [ Time Frame: baseline up to approximately 30 months ]
    Change from baseline in EORTC Quality of Life Questionnaire Core 30
  • Event-free survival
  • Disease-free survival
  • Overall survival
  • Time to next treatment
  • Overall response rate, complete response, and partial response according to NCI criteria
  • Rates of phenotypic response (minimal residual disease)
  • Duration of phenotypic and NCI clinical responses
  • Response rates and time-related parameters in biological subgroups
  • Rates of treatment-related adverse events
  • CD4/CD8 counts, immunoglobulin levels, and incidence of Coombs-positive hemolytic anemia
  • Pharmacokinetics of rituximab during induction and maintenance
  • Prognostic impact of the immunoglobulin FcγRIIIA genotype
  • Quality of life
  • Pharmacoeconomics
Not Provided
Not Provided
 
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia
Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO

RATIONALE: Classical chemotherapy does not cure advanced chronic lymphocytic leukemia (CLL) despite new drugs. Rituximab is a monoclonal antibody directed against CD20 surface antigen on B lymphocytes and leads to apoptosis of CD20 positive B lymphocytes. The highest response rate yet published in the treatment of first-line CLL has been obtained by the association of fludarabine, cyclophosphamide and rituximab (FCR). Now, the question is whether this response can be improved, as some trials showed that eradication of minimal residual disease (MRD) in CLL is associated with a longer treatment-free and overall survival. Maintenance therapy using rituximab has been recently approved as a means of prolonging remission in patients with indolent non Hodgkin's lymphoma. Maintenance therapy with rituximab could be of interest in treatment of MRD in CLL and prolonging remission and survival times.

PURPOSE: The overall purpose of the study is to determine the value of immunotherapy maintenance with single agent rituximab in comparison with no further treatment (observation ) for previously untreated chronic lymphocytic leukaemia in elderly (>65 years) patients who respond to induction immunochemotherapy with FCR.

OBJECTIVES:

Primary

  • To demonstrate superiority, in terms of 3-year progression-free survival (PFS), of rituximab maintenance over observation in patients who are in complete or partial response (CR or PR) after induction therapy comprising fludarabine, cyclophosphamide, and rituximab.

Secondary

  • To determine event-free survival, disease-free survival, overall survival, and time to next treatment, all from time of randomization.
  • To determine overall response rate (CR and PR) according to NCI and iwCLL criteria
  • To assess the rate of phenotypic response (minimal residual disease).
  • To assess duration of phenotypic and NCI and iwCLL clinical responses.
  • To determine response rates and time-related parameters in biological subgroups.
  • To determine rates of treatment-related adverse events.
  • To evaluate CD4/CD8 counts, immunoglobulin levels, and incidence of Coombs-positive hemolytic anemia.
  • To study pharmacokinetics of rituximab during induction and maintenance.
  • To evaluate the prognostic impact of the immunoglobulin FcγRIIIA genotype.
  • To assess quality of life.
  • To study pharmacoeconomics.

OUTLINE: This is a multicenter study. Randomization is stratified according to response to induction therapy (complete response [CR] vs partial response [PR]), IGHV mutational status, and 11q deletion.

Patients receive rituximab IV on days 1 and 14 of courses 1-2 and on day 1 of courses 3 and 4. Patients also receive oral fludarabine and oral cyclophosphamide once daily on days 2-4 of course 1 and on days 1-3 of courses 2-4. Courses are administered every 28 days. Patients achieving CR or PR are randomized 1:1 to maintenance arm or observation arm.

  • Arm A: Patients receive rituximab IV every 2 months in the absence of disease progression or unacceptable toxicity for a maximum duration of 24 months (12 infusions).
  • Arm B: Patients undergo observation only.

After completion of study therapy, patients are followed every 3 months for 1 year and then every 6 months for 2 years.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Leukemia
Biological: Rituximab
rituximab :500 mg/m² every 8 weeks during 2 years
Other Name: Mabthera
  • No Intervention: Observation
    Observation every 8 weeks during 2 years
  • Experimental: rituximab arm
    rituximab :500 mg/m² every 8 weeks during 2 years
    Intervention: Biological: Rituximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
542
July 2017
February 2014   (Final data collection date for primary outcome measure)

Inclusion criteria

  • B-CLL
  • Matutes score 4 or 5
  • Binet stages B or C
  • Age > 65 years old
  • No previous treatment of CLL by chemotherapy, radiotherapy or immunotherapy, except glucocorticoids < 1 month
  • Patient's written informed consent
  • Life expectancy > 6 months

Exclusion criteria

  • Binet stage A
  • ECOG performance status 2 or more
  • Presence of a 17p deletion by FISH (> 10% positive cores)
  • Clinically significant auto-immune cytopenia, Coombs-positive hemolytic anemia as judged by the treating physician
  • Patients with a history of another malignancy in complete remission less than 5 years, except basal cell skin cancer or tumor treated curatively by surgery
  • Concomitant disease requiring prolonged use of corticosteroids (> 1 month)
  • Any severe co-morbidities such as NYHA Class III or IV heart failure, myocardial infarction within 6 months, unstable angina, ventricular tachyarrhythmias requiring ongoing treatment, severe uncontrolled myocardiopathy, uncontrolled hypertension, severe chronic obstructive pulmonary disease with hypoxemia, or uncontrolled diabetes mellitus.
  • CIRS (Cumulative Illness rating Scale) > 6
  • Known hypersensitivity to murine proteins or to any of the study drugs or to their components
  • Transformation into an aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma) or prolymphocytic leukemia
  • Active bacterial, viral or fungal infection
  • Seropositivity HIV, hepatitis C or hepatitis B (unless clearly due to vaccination)
  • Total bilirubin, alkaline phosphatases and aminotransferases > 2 x ULN
  • Creatinine clearance < 60 ml/min calculated according to the formula of Cockcroft and Gault
  • Any coexisting medical or psychological condition that would preclude participation to the required study procedures
  • Patient with mental deficiency preventing proper understanding of the requirements of treatment

Inclusion criteria at randomization

  • Patients having received the full induction phase with 4 FC and 6 rituximab courses (with/without dose adjustments as per protocol)
  • Complete or partial response according to NCI and iwCLL criteria at the end of induction phase
  • Recovery from FCR toxicities
  • Patient willingness to continue on protocol
Sexes Eligible for Study: All
65 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00645606
CDR0000589684
CHRUT-LLC-2007-SA ( Other Identifier: CHU Tours )
CHRUT-PHRN05-CD ( Other Identifier: CHU Tours )
INCA-RECF0497 ( Other Identifier: INCA )
2007-001015-28 ( EudraCT Number )
Yes
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Plan to Share IPD: No
University Hospital, Tours
University Hospital, Tours
  • Roche Pharma AG
  • French Innovative Leukemia Organisation
Principal Investigator: Caroline Dartigeas, MD Hématologie et Thérapie Cellulaire Hôpital Bretonneau CHU Tours FRANCE
Principal Investigator: Eric VAN DEN NESTE, MD PhD Département d'hématologie Cliniques Universitaires Saint Luc BRUSSELS BELGIUM
University Hospital, Tours
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP